By incorporating a stably expressed Cas9 nuclease into Revvity’s HAP1 LIG4(-) cell line, the Sanger Institute has generated a new cell line that is highly amenable to efficient CRISPR/Cas9-mediated genomic modifications.
Read our interview with Dr. Sebastian Gerety, Principal Staff Scientist in the Human Genetics Program at the Sanger Institute, in which he discusses:
For research use only. Not for use in diagnostic procedures.
Generating a clonal HAP1LIG4(-) Cas9(+) cell line – an expert interview